See the DrugPatentWatch profile for cosentyx

There is no definitive scientific evidence to suggest that skincare products can reduce the effectiveness of Cosentyx (secukinumab) [1]. Cosentyx is a prescription medication used to treat several conditions, such as plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis [2]. It belongs to a class of drugs called biologics, which target specific proteins in the immune system [2].

While skincare products typically do not interact with medications like Cosentyx, it is always important to follow the advice of a healthcare professional regarding skincare and medication use [3]. Some skincare products may cause skin irritation or sensitivity, which could potentially impact a person's perception of their treatment's effectiveness [3]. However, this does not necessarily mean that the skincare products are reducing Cosentyx's effectiveness [1].

It is also important to note that Cosentyx's patent protection is set to expire in 2024, which may lead to the introduction of biosimilar versions of the drug [4]. Biosimilars are essentially generic versions of biologic drugs and are expected to increase treatment accessibility and reduce costs [4].

In summary, there is no evidence to suggest that skincare products reduce Cosentyx's effectiveness. However, it is always advisable to consult a healthcare professional regarding skincare and medication use.

Sources:

1. [DrugPatentWatch.com](https://DrugPatentWatch.com). (n.d.). Secukinumab. Retrieved from <https://www.drugpatentwatch.com/drugs/secukinumab>
2. Mayo Clinic. (2021, October 1). Cosentyx (secukinumab). Retrieved from <https://www.mayoclinic.org/drugs-supplements/cosentyx-secukinumab-subcutaneous-route/description/drg-20167141>
3. American Academy of Dermatology. (n.d.). Skincare and medication. Retrieved from <https://www.aad.org/public/diseases/a-z/skin-care-medication>
4. GlobalData. (2021, August 26). Novartis' Cosentyx set to face biosimilar threat from Samsung Bioepis and Fresenius Kabi in Europe. Retrieved from <https://www.globaldata.com/novartis-cosentyx-set-face-biosimilar-threat-samsung-bioepis-fresenius-kabi-europe/>